Brief: Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Denali Therapeutics

06/01/2025 23:20

Jan 6 (Reuters) - Denali Therapeutics Inc  DNLI.O :
    * DENALI THERAPEUTICS ANNOUNCES TOPLINE RESULTS FOR REGIMEN
G
EVALUATING EIF2B AGONIST DNL343 IN THE PHASE 2/3 HEALEY ALS
PLATFORM TRIAL
    * DENALI THERAPEUTICS INC - STUDY DID NOT MEET PRIMARY
ENDPOINT OF
SLOWING DISEASE PROGRESSION
    * DENALI THERAPEUTICS INC - DNL343 FOUND TO BE SAFE AND WELL
TOLERATED
    * DENALI THERAPEUTICS INC - KEY SECONDARY ENDPOINTS NOT
STATISTICALLY DIFFERENT AT WEEK 24

Source text:  ID:nGNXbtw9Bj 
Further company coverage:  DNLI.O 

 ((Reuters.Briefs@thomsonreuters.com;))